(Q41469651)

1 October 2017

title

Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin (English)

1 reference

1 October 2017

1 reference

1 reference

1 reference

Masanori Atsukawa

1

1 reference

1 October 2017

Akihito Tsubota

2

1 reference

1 October 2017

Noritomo Shimada

3

1 reference

1 October 2017

Kai Yoshizawa

4

1 reference

1 October 2017

Hiroshi Abe

5

1 reference

1 October 2017

Toru Asano

6

1 reference

1 October 2017

Yusuke Ohkubo

7

1 reference

1 October 2017

Masahiro Araki

8

1 reference

1 October 2017

Tadashi Ikegami

9

1 reference

1 October 2017

Tomomi Okubo

10

1 reference

1 October 2017

Chisa Kondo

11

1 reference

1 October 2017

Yuji Osada

12

1 reference

1 October 2017

Katsuhisa Nakatsuka

13

1 reference

1 October 2017

Yoshimichi Chuganji

14

1 reference

1 October 2017

Yasushi Matsuzaki

15

1 reference

1 October 2017

Katsuhiko Iwakiri

16

1 reference

1 October 2017

Yoshio Aizawa

17

1 reference

1 October 2017

publication date

20 August 2015

1 reference

1 October 2017

1 reference

1 October 2017

volume

46

1 reference

1 October 2017

issue

5

1 reference

1 October 2017

page(s)

450-458

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

25-Hydroxyvitamin D3 suppresses hepatitis C virus production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

Interferon-free strategies with a nucleoside/nucleotide analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

HCV direct-acting antiviral agents: the best interferon-free combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12575

21 January 2018

Identifiers

DOI

10.1111/HEPR.12575

1 reference

1 October 2017

1 reference